SOPHiA GENETICS Debuts MSK-IMPACT® with SOPHiA DDM™ at AMP 2024

SOPHiA GENETICS, a leader in cloud-native healthcare technology, has announced the worldwide launch of the MSK-IMPACT® application powered with SOPHiA DDM™. This announcement was made at the Association for Molecular Pathology (AMP) Annual Meeting. This groundbreaking solution enables global access to Memorial Sloan Kettering Cancer Center (MSK)'s comprehensive genomic profiling (CGP) application, providing high accuracy and efficiency.

The introduction of MSK-IMPACT® powered with SOPHiA DDM™ marks a significant advancement in precision oncology. Philippe Menu, M.D., Ph.D., Chief Product Officer and Chief Medical Officer at SOPHiA GENETICS, emphasized the company's dedication to expanding access to data-driven medicine. The launch follows the successful release of MSK-ACCESS® powered with SOPHiA DDM™ earlier this year, highlighting the strong collaboration between SOPHiA GENETICS and MSK. Menu expressed excitement about decentralizing advanced tumor profiling technologies, making them more accessible, especially to underserved populations.

Kojo S. J. Elenitoba-Johnson, M.D., Chair of the Department of Pathology and Laboratory Medicine at MSK, echoed these sentiments, highlighting the shared vision with SOPHiA GENETICS to advance precision medicine and make leading tests more accessible to patients globally.

MSK-IMPACT® powered with SOPHiA DDM™ enhances the accuracy of somatic mutation detection, including in critical genes for pharmaceutical R&D, such as MTAP. The matched tumor-normal analysis approach allows for more confident detection of somatic mutations, reducing the risk of misclassifying germline variants as tumor-specific. Additionally, institutions benefit from the global collective intelligence fostered by SOPHiA GENETICS' network, providing real-world data and insights from diverse populations.

SOFIVA GENOMICS, a leading molecular diagnostics company in Taiwan, is among the first to adopt this new application. The company initially partnered with SOPHiA GENETICS in 2022 to utilize the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution. Now, SOFIVA GENOMICS is expanding its capabilities by incorporating MSK-IMPACT® powered with SOPHiA DDM™ alongside the MSK-ACCESS® liquid biopsy test. Chia-Cheng Hung, General Manager of SOFIVA GENOMICS, noted that the partnership has significantly enhanced their ability to provide precise genomic testing, facilitating progress in cancer research in Taiwan.

The MSK-IMPACT® powered with SOPHiA DDM™ ensures a more efficient workflow, with the entire process from DNA extraction to final report completion taking around five days. Clinicians and researchers gain access to OncoKB™, MSK's Precision Oncology Knowledge Base, which enhances the interpretive power of the analysis through data-driven insights. In-house analytical validation results for the application showed high concordance with the single-site MSK-IMPACT® test, achieving notable accuracy in various detection metrics, including:
- 99.3% positive percent agreement (PPA) for SNV/Indel detection,
- 94.6% PPA for copy number variant (CNV) detection,
- 99.4% overall percent agreement (OPA) for microsatellite instability (MSI) detection,
- 98.8% OPA for tumor mutational burden (TMB) detection.

These results underscore the reliability and precision of the MSK-IMPACT® powered with SOPHiA DDM™, positioning it as a vital tool in the advancement of oncology research and treatment.